E4NA Stock Chart & Stats
€0.04
€0.00(0.00%)
At close: 4:00 PM EDT
€0.04
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.04 - €0.06
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€44.99M
Enterprise Value€60.24
Total Cash (Recent Filing)€14.35M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.10
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,208,851,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)5.26
Price to Sales (P/S)0.00
P/FCF Ratio-10.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal LeverageMinimal leverage limits interest and refinancing pressure, giving Arovella greater financial flexibility while its therapies remain in development and reducing near-term solvency risk relative to more indebted biotechs.
Positive Equity PositionAssets exceeding liabilities provide a supportive capital base for an early-stage company. Positive equity does not remove funding needs, but it offers more balance-sheet resilience as Arovella advances its immunotherapy programs.
Improving Free Cash Flow TrendThe improvement in free cash flow indicates some moderation in cash outflows compared with the prior year. If sustained, this could extend the runway available to fund research and clinical development.
Bears Say
No Scalable Commercial RevenueRevenue falling to zero shows that Arovella has not yet established a dependable commercial base. This leaves future value heavily dependent on clinical progress, partnerships or external financing rather than recurring product sales.
Persistent Operating LossesRecurring operating and net losses indicate that the current business model is not yet economically self-sustaining. Without successful development and commercialization, continued losses may constrain investment capacity and require additional capital.
Ongoing Cash Funding DependenceSustained operating cash burn means Arovella remains reliant on external funding to maintain research and development. This creates financing and potential dilution risk, even though current leverage is minimal.
Arovella Therapeutics Limited News
E4NA FAQ
What was Arovella Therapeutics Limited’s price range in the past 12 months?
Arovella Therapeutics Limited lowest stock price was €0.04 and its highest was €0.06 in the past 12 months.
What is Arovella Therapeutics Limited’s market cap?
Arovella Therapeutics Limited’s market cap is €44.99M.
When is Arovella Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Arovella Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Arovella Therapeutics Limited overvalued?
According to Wall Street analysts Arovella Therapeutics Limited’s price is currently Overvalued.
Does Arovella Therapeutics Limited pay dividends?
Arovella Therapeutics Limited does not currently pay dividends.
What is Arovella Therapeutics Limited’s EPS estimate?
Arovella Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arovella Therapeutics Limited have?
Arovella Therapeutics Limited has 1,208,851,800 shares outstanding.
What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Arovella Therapeutics Limited?
Currently, no hedge funds are holding shares in DE:E4NA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arovella Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:E4NA Sentiment 83%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth €8.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Arovella Therapeutics Limited
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
Technical Analysis
Imugene
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Radiopharm Theranostics Limited
―
Recce Pharmaceuticals Ltd.
―